Скачать или смотреть How does Donanemab compare to other Alzheimer's drugs? | Morning in America

Eli Lilly and Co. is seeking FDA approval for Donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease. Dr. Ian Smith weighs out the pros and cons of this drug's ability to slow Alzheimer's.

Watch #MorningInAmerica: https://www.newsnationnow.com/joinus

#Alzheimers #FDA #Donanemab

Start your day with "Morning in America," NewsNation's live three-hour national morning newscast hosted by Adrienne Bankert. Weekdays starting at 7a/6C. #MorningInAmerica

NewsNation is your source for fact-based, unbiased news for all America.

More from NewsNation: https://www.newsnationnow.com/
Get our app: https://trib.al/TBXgYpp
Find us on cable: https://trib.al/YDOpGyG
How to watch on TV or streaming: https://trib.al/Vu0Ikij